Consumer Insights
Uncover trends and behaviors shaping consumer choices today
Procurement Insights
Optimize your sourcing strategy with key market data
Industry Stats
Stay ahead with the latest trends and market analysis.
Explore Our Diverse Range Of Offerings
From detailed reports to experts services offered in 15+
Industry Domains
Add 2 More Reports For 20% off
Report Overview
Recurrent malignant glioma remains among the most aggressive and therapeutically complex central nervous system tumors, marked by an almost inevitable relapse after standard interventions. As per David Sipos et al., 2025, high-grade gliomas, including glioblastoma, have a global incidence of approximately 3–5 cases per 100,000 individuals annually. According to recurrent malignant glioma pipeline analysis by Expert Market Research, sustained clinical trial activity reflects urgent demand for novel targeted therapies and innovative biologics to address poor survival outcomes. While distinct from ophthalmic disorders such as refractive errors, myopia progression, and astigmatism correction therapies, both fields emphasize precision medicine and advanced therapeutic innovation.
-
Major companies involved in the recurrent malignant glioma pipeline analysis include BeiGene USA, Inc., Xynomic Pharmaceuticals, Inc., and others.
-
Leading drugs currently in the pipeline include PCI 24781, CUE-102, and others.
-
The pipeline growth is driven by rising disease burden, advances in targeted therapies, expansion of clinical trials, increasing precision medicine, strong biotech collaborations, regulatory incentives, and innovation in drug delivery technologies, accelerating development of effective treatment options.
Report Coverage
The Recurrent Malignant Glioma Pipeline Analysis Report by Expert Market Research gives comprehensive insights into recurrent malignant glioma therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for recurrent malignant glioma. The recurrent malignant glioma report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The recurrent malignant glioma pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with recurrent malignant glioma treatment guidelines to ensure optimal care practices.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to recurrent malignant glioma.
Read more about this report - Request a Free Sample
Recurrent Malignant Glioma Pipeline Outlook
Recurrent malignant glioma is an aggressive central nervous system tumor marked by inevitable relapse and poor survival outcomes. Despite initial interventions, disease progression persists due to tumor heterogeneity, resistance mechanisms, and limited efficacy of existing therapies, reinforcing significant unmet need for novel oncology solutions.
Current management includes surgical resection, re-irradiation strategies, and chemotherapy rechallenge alongside anti-angiogenic therapies; however, long-term benefits remain limited. Ongoing advancements emphasize precision oncology, targeted drug development, and innovative approaches to improve therapeutic durability. For instance, in August 2025, the FDA granted accelerated approval to dordaviprone (Modeyso), a first-in-class oral imipridone, for H3 K27M-mutant diffuse glioma, including recurrent disease after prior therapy, marking a significant advancement for this rare and difficult-to-treat subtype.
Recurrent Malignant Glioma Epidemiology
Recurrent malignant glioma most often follows relapse of high-grade gliomas, particularly glioblastoma, the most common and aggressive primary malignant brain tumor worldwide. Glioblastoma accounts for 45-50% of all gliomas, with a global incidence of about 2 to 5 cases per 100,000 individuals annually, translating to roughly 250,000 new cases each year. It predominantly affects older adults, with incidence rising with age, peaking in the sixth and seventh decades of life, and showing a modest male predominance. Despite standard therapy, recurrence is nearly universal, underscoring substantial unmet clinical need This persistent challenge parallels the growing burden seen in vision disorders such as refractive eye conditions, blurred vision disorders, and visual impairment management, where continuous innovation is required to address long-term disease burden.
Recurrent Malignant Glioma – Pipeline Therapeutic Assessment
This section of the report covers the analysis of recurrent malignant glioma drug candidates based on several segmentations, including:
By Phase
The pipeline assessment report covers 50+ drug analyses based on phase:
- Late-Stage Products (Phase 3 and Phase 4)
- Mid-Stage Products (Phase 2)
- Early-Stage Products (Phase 1)
- Preclinical and Discovery Stage Products
By Drug Class
The recurrent malignant glioma pipeline analysis report covers 50+ drug analyses based on drug classes:
- Small Molecules
- Monoclonal Antibodies
- Peptides
By Route of Administration
The pipeline assessment report covers 50+ drug analyses based on the route of administration:
- Oral
- Parenteral
- Others
Recurrent Malignant Glioma Pipeline Assessment Segmentation, By Phases
The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase I covers a major share of the total recurrent malignant glioma clinical trials. The report covers phase I (62%), phase II (27%), and early-phase I (10%) drugs in recurrent malignant glioma clinical trials. This distribution highlights strong early-stage research activity and a growing focus on innovative therapeutic approaches.
Recurrent Malignant Glioma Pipeline Assessment Segmentation, By Drug Classes
The drug molecule categories covered under the recurrent malignant glioma pipeline analysis include small molecules, monoclonal antibodies, and peptides. The recurrent malignant glioma report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for recurrent malignant glioma. For instance, in August 2024, the FDA approved vorasidenib (VORANIGO) as a targeted therapy for Grade 2 IDH-mutant glioma, including residual or recurrent tumors with IDH1/IDH2 mutations, improving progression-free survival and expanding precision treatment approaches in gliomas.
Recurrent Malignant Glioma Clinical Trials – Key Players
The EMR report for the recurrent malignant glioma pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed recurrent malignant glioma therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in recurrent malignant glioma clinical trials:
- Trogenix Ltd.
- Northwell Health
- AstraZeneca
- Cue Biopharma
- DNAtrix, Inc.
- GlaxoSmithKline
- Xynomic Pharmaceuticals, Inc.
- BeiGene USA, Inc.
- Jazz Pharmaceuticals
- Incuron LLC
Recurrent Malignant Glioma – Emerging Drugs Profile
This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for recurrent malignant glioma. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of recurrent malignant glioma drug candidates.
BIOLOGICAL: MVR-C5252
MVR-C5252 is an oncolytic herpes simplex virus-1 (oHSV-1) biologic developed by ImmVira, engineered to express interleukin-12 (IL-12) and an anti-PD-1 antibody for dual oncolysis and immune activation against recurrent high-grade glioma. Upon intracranial convection-enhanced delivery, it infects and lyses tumor cells while secreting IL-12 and PD-1 blockade to stimulate adaptive immunity within the tumor microenvironment. Early Phase 1 data show a favorable safety profile and immune engagement. ImmVira’s proprietary OVPENS platform underpins this novel approach, with collaboration from institutions such as Duke University driving clinical progress.
BIOLOGICAL: CUE-102
CUE-102 is a biologic Fc-fusion immunotherapy from Cue Biopharma’s Immuno-STAT® platform designed to selectively activate and expand Wilms’ Tumor 1 (WT1)-specific T cells in patients with WT1-expressing cancers, including recurrent glioblastoma. By presenting WT1 peptide and engineered interleukin-2 signals, it enhances tumor antigen-specific immune responses. Currently in Phase 1 evaluation, CUE-102 has shown encouraging tolerability and potential antitumor activity in early studies. Cue Biopharma’s immunomodulatory focus and proprietary platform aim to create precision immune therapies with reduced systemic toxicity.
Drug: PCI 24781
PCI-24781, also known as Abexinostat, is a small-molecule pan-histone deacetylase (HDAC) inhibitor developed by the University of Nebraska in collaboration with Xynomic Pharmaceuticals. By inhibiting multiple HDAC enzyme classes, it disrupts chromatin regulation, re-expresses tumor suppressor genes, induces apoptosis, and increases reactive oxygen species, resulting in antitumor effects. While initially explored in hematologic malignancies and solid tumors, including glioma combinations, PCI-24781’s mechanism targets epigenetic modulation to halt cancer cell growth. Xynomic continues its clinical development across indications, with ongoing interest in in integrating HDAC inhibition into combination regimens.
*Please note that this is only a partial list; the complete list of drugs will be available in the full report.*
Key Questions Answered in the Recurrent Malignant Glioma Pipeline Insight Report
- Which companies/institutions are leading recurrent malignant glioma drug development?
- Which company is leading the recurrent malignant glioma pipeline development activities?
- What is the current recurrent malignant glioma commercial assessment?
- What are the opportunities and challenges present in the recurrent malignant glioma pipeline landscape?
- What is the efficacy and safety profile of recurrent malignant glioma pipeline drugs?
- Which company is conducting major trials for recurrent malignant glioma drugs?
- Which companies/institutions are involved in recurrent malignant glioma collaborations aimed at providing enhanced therapeutic alternatives for patients?
- What are the geographies covered for clinical trials in recurrent malignant glioma?
Reasons To Buy This Report
The Recurrent Malignant Glioma Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for recurrent malignant glioma. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into recurrent malignant glioma collaborations, regulatory environments, and potential growth opportunities.
Related Reports
Pricing Plans
Upto 15% Off
USD
-
$1999 $1799
-
$3099 $2789
-
$4599 $3909
-
$5999 $5099
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Report Summary
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
|
Scope of the Report |
Details |
|
Drug Pipeline by Clinical Trial Phase |
|
|
Route of Administration |
|
|
Drug Classes |
|
|
Leading Sponsors Covered |
|
|
Geographies Covered |
|
Mini Report
One User
USD 1,999
USD 1,799
tax inclusive*
- Selected Segments
- Printing Restrictions
- Excel Spreadsheet Delivered via Email
- Full Report
- Periodic Updates
- Post Sales Analysts Support
- Unlimited Prints
Single User License
One User
USD 3,099
USD 2,789
tax inclusive*
- All Segments
- Printing Restrictions
- PDF Delivered via Email
- Custom Report Layout
- Post Sales Analysts Support
- Periodic Updates
- Unlimited Prints
Five User License
Five User
USD 4,599
USD 3,909
tax inclusive*
- All Segments
- Five Prints Available
- PDF Delivered via Email
- Limited Free Customization
- Post Sales Analyst Support
- Custom Report Layout
- Periodic Updates
- Unlimited Prints
Corporate License
Unlimited Users
USD 5,999
USD 5,099
tax inclusive*
- All Segments
- Unlimited Prints Available
- PDF & Excel Delivery via Email
- Limited Free Customization
- Post Sales Analysts Support
- Discount On Next Update
- Custom Report Layout
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Bundle Type
Flash Bundle
20% OFF
Number of Reports: 3
Small Business Bundle
25% OFF
Number of Reports: 5
Growth Bundle
30% OFF
Number of Reports: 8
Enterprise Bundle
35% OFF
Number of Reports: 10
Overview
- Life Time Access
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours
- Complimentary Free 1 Month Subscription to Trade Data Base
- Complimentary One Month Subscription to Price Database (Chemicals only)
- Complimentary PPT Version of the Report
- Complimentary License Upgrade
- Complimentary Power BI Dashboards
- Life Time Access
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 50 Hours
- Complimentary Free 1 Month Subscription to Trade Data Base
- Complimentary One Month Subscription to Price Database (Chemicals only)
- Complimentary PPT Version of the Report
- Complimentary License Upgrade
- Complimentary Power BI Dashboards
- Life Time Access
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 80 Hours
- Complimentary Free 1 Month Subscription to Trade Data Base
- Complimentary One Month Subscription to Price Database (Chemicals only)
- Complimentary PPT Version of the Report
- Complimentary License Upgrade
- Complimentary Power BI Dashboards
- Life Time Access
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 100 Hours
- Complimentary Free 1 Month Subscription to Trade Data Base
- Complimentary One Month Subscription to Price Database (Chemicals only)
- Complimentary PPT Version of the Report
- Complimentary License Upgrade
- Complimentary Power BI Dashboards
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
- 3 Reports Included
- Life Time Acess
- Analyst Support Related to Report
- PDF Version of the Report
- Free 1 Month Subscription to Trade Data Base
- 1 Month Subscription to Price Database (Chemicals only)
- Complimentary Excel Data Set
- PPT Version of the Report
- Power BI Dashboards
- License Upgrade
- Free Analyst Hours
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
- 5 Reports Included
- Life Time Acess
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 50 Hours
- Free 1 Month Subscription to Trade Data Base
- 1 Month Subscription to Price Database (Chemicals only)
- Complimentary Excel Data Set
- PPT Version of the Report
- Power BI Dashboards
- License Upgrade
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
- 8 Reports Included
- Life Time Acess
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 50 Hours
- Free 1 Month Subscription to Trade Data Base
- 1 Month Subscription to Price Database (Chemicals only)
- License Upgrade
- Free Analyst Hours - 80 Hours
- Power BI Dashboards
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
- 10 Reports Included
- Life Time Acess
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 50 Hours
- Free 1 Month Subscription to Trade Data Base
- 1 Month Subscription to Price Database (Chemicals only)
- License Upgrade
- Power BI Dashboards
- Free Analyst Hours - 100 Hours
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Strategic Solutions for Informed Decision-Making
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
